In order to run the TLC plate and conduct the analysis in a point of care setting, the fumes from the mobile phase and silica dust from the TLC plates need to be contained such that patients and health care workers are not exposed to them. This means that the mobile phase needs to be separated from the TLC plate until it is time to develop it after the samples have been loaded. In order to accomplish this, the cartridge has a two-chamber design which separates the TLC plate from the mobile phase (Figure ). There is a breakable seal between the two chambers that once opened allows the mobile phase to contact the TLC plate and begin developing it, but only when the cartridge is tilted upright. Figure shows the samples are loaded onto the TLC plate, including a set of samples with defined concentrations of DOX, DOL, and an internal standard epirubicin (EPI) to create a standard curve along with the patient sample. These samples are loaded on the TLC plate using a needle to penetrate through a rubber septum that maintains the hermetic seal before and after sample loading. A needle was then placed through a rubber septum to break the seal between the two chambers, in this case a glass coverslip, while maintaining the hermetic seal. The whole cartridge was then tilted 90° to allow the mobile phase to flow through the now opened barrier and contact the TLC plate. The plate was allowed to develop separating the drug, metabolites and internal standard. The TLC plate was stopped from developing by laying the cartridge down flat again allowing the mobile phase to drain out of the TLC plate chamber. The plate was then imaged through the clear front of the cartridge for drug and metabolite quantification with the PXI imaging system. Custom optical fluorescence quantification software was used to determine the plasma concentration of the drug based on the resulting compound bands.